Almorexant Hydrochloride Catalog No.:M8931-10 Smiles: CC(C)(C)[C@H](NC(=O)COCCOCCOCCCCCCN1C[C@H](COC2N=C(N=C3NN=CC=23)C2C=CC(=CC=2)NS(=O)(=O)C2=CC(C)=CC=C2F)OCC1)C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC1C=CC(=CC=1)C1SC=NC=1C

Smiles: CC(C)(C)[C@H](NC(=O)COCCOCCOCCCCCCN1C[C@H](COC2N=C(N=C3NN=CC=23)C2C=CC(=CC=2)NS(=O)(=O)C2=CC(C)=CC=C2F)OCC1)C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC1C=CC(=CC=1)C1SC=NC=1C

1 channel activator

Molecular Weight: 810

CAS Number: 72-14-0

A1207 and LN-Z30 cells

Almorexant Hydrochloride Catalog No.:M8931-10 Smiles: CC(C)(C)[C@H](NC(=O)COCCOCCOCCCCCCN1C[C@H](COC2N=C(N=C3NN=CC=23)C2C=CC(=CC=2)NS(=O)(=O)C2=CC(C)=CC=C2F)OCC1)C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC1C=CC(=CC=1)C1SC=NC=1CAlmorexant HCl, also known as ACT 078573, is an orexin antagonist, functioning as a competitive receptor antagonist of the OX1 and OX2 orexin receptors, which was being developed by the pharmaceutical companies Actelion and GSK for the treatment of insomnia. Development of the drug was abandoned in January 2011. Almorexant is a competitive, dual OX1 and OX2 receptor antagonist and selectively inhibits the functional consequences of OX1 and OX2